BioMarin expects Alesta acquisition to cut full-year 2026 GAAP, non-GAAP diluted EPS by about $1.55
BMRN•BioMarin expects the Alesta acquisition to generate about $320 million in pre-tax charges in 2026, reducing both GAAP and non-GAAP diluted EPS by about $1.55 for the year.
1. Expected acquisition charges
BioMarin expects about $283 million of acquired IPR&D expense in the third quarter of 2026, following the acquisition’s completion on Aug. 31. It estimates the quarter’s impact at about $1.50 per share on both GAAP and non-GAAP diluted EPS, and plans to update its 2026 guidance with third-quarter results; its Aug. 6 outlook excluded Alesta.
